uniQure - QURE Stock Forecast, Price & News

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Analysts Set New Price Targets

A number of research firms have weighed in on QURE. TheStreet cut shares of uniQure from a "c-" rating to a "d" rating in a research note on Tuesday, August 9th. Wells Fargo & Company decreased their target price on shares of uniQure from $34.00 to $24.00 and set an "equal weight" rating on the stock in a research note on Tuesday, August 9th. StockNews.com cut shares of uniQure from a "hold" rating to a "sell" rating in a research note on Wednesday, August 10th. Chardan Capital reduced their price objective on shares of uniQure from $65.00 to $60.00 and set a "buy" rating on the stock in a research note on Tuesday, August 9th. Finally, Stifel Nicolaus reduced their price objective on shares of uniQure from $66.00 to $37.00 in a research note on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average price target of $48.38.

uniQure Trading Up 0.2 %

QURE Stock traded up $0.03 during midday trading on Thursday, hitting $18.72. The stock had a trading volume of 2,941 shares, compared to its average volume of 801,664. The firm has a market cap of $874.79 million, a P/E ratio of -7.63 and a beta of 1.01. The company has a current ratio of 10.84, a quick ratio of 10.78 and a debt-to-equity ratio of 0.21. uniQure has a 1-year low of $12.52 and a 1-year high of $38.80. The business has a fifty day moving average price of $20.39 and a two-hundred day moving average price of $17.74.

Insider Activity at uniQure

In related news, VP Alexander Edward Kuta III sold 5,643 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $25.00, for a total value of $141,075.00. Following the transaction, the vice president now owns 95,196 shares in the company, valued at $2,379,900. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, VP Alexander Edward Kuta III sold 5,643 shares of the company's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $25.00, for a total transaction of $141,075.00. Following the transaction, the vice president now owns 95,196 shares in the company, valued at $2,379,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Pierre Caloz sold 7,575 shares of the company's stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $13.21, for a total transaction of $100,065.75. Following the transaction, the chief operating officer now owns 64,511 shares in the company, valued at approximately $852,190.31. The disclosure for this sale can be found here. Insiders have sold a total of 42,263 shares of company stock worth $947,359 over the last quarter. Company insiders own 3.10% of the company's stock.